192 related articles for article (PubMed ID: 20636437)
1. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
2. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
3. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Mentz K; Singer H; Stockmeyer B; Hillen W; Mackensen A; Fey GH
MAbs; 2011; 3(1):21-30. PubMed ID: 21081841
[TBL] [Abstract][Full Text] [Related]
4. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.
Stein C; Kellner C; Kügler M; Reiff N; Mentz K; Schwenkert M; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Mar; 148(6):879-89. PubMed ID: 20064159
[TBL] [Abstract][Full Text] [Related]
5. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
6. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
8. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH
MAbs; 2012; 4(1):45-56. PubMed ID: 22327429
[TBL] [Abstract][Full Text] [Related]
9. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
10. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
Schirrmann T; Pecher G
Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
[TBL] [Abstract][Full Text] [Related]
11. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
[TBL] [Abstract][Full Text] [Related]
12. Expression of an anti-CD33 single-chain antibody by Pichia pastoris.
Emberson LM; Trivett AJ; Blower PJ; Nicholls PJ
J Immunol Methods; 2005 Oct; 305(2):135-51. PubMed ID: 16139294
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
14. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
[TBL] [Abstract][Full Text] [Related]
15. The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation.
Ericson SG; Benoit NE; Mills LE; Fanger MW
Exp Hematol; 1994 Mar; 22(3):283-9. PubMed ID: 7509291
[TBL] [Abstract][Full Text] [Related]
16. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2004 Oct; 10(20):7043-52. PubMed ID: 15501984
[TBL] [Abstract][Full Text] [Related]
17. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia.
Retnakumari A; Jayasimhan J; Chandran P; Menon D; Nair S; Mony U; Koyakutty M
Nanotechnology; 2011 Jul; 22(28):285102. PubMed ID: 21654031
[TBL] [Abstract][Full Text] [Related]
18. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
20. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
